Compare Amgen, Inc. (AMGN) vs Datadog Inc (DDOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Datadog Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Datadog Inc trades at $259.21 (market cap $91.67B). The key difference: Amgen, Inc. is far larger — about 2.1× Datadog Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.
| AMGN | DDOG | |
|---|---|---|
Market Cap | $196.12B | $91.67B |
Sector | Health | Technology |
52-Week High | $388.16 | $277.49 |
52-Week Low | $271.18 | $102.62 |
Enterprise Value | $241.41B | $88.20B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Datadog (DDOG) trades at $257.54, down 4.25% on the day, with strong technical momentum indicators showing bullish moving averages but overbought RSI readings. The company maintains impressive revenue growth, reaching $3.43B in 2025, with consistent earnings beats in recent quarters. Recent acquisition of Adaptive ML positions DDOG for AI-driven growth, though valuation metrics remain elevated with P/E of 660 and P/S of 25.5.
Outlook remains positive with 83% analyst buy ratings and $246 consensus target, though current price exceeds target. Key risks include high valuation multiples, moderating growth guidance, and competitive pressures in cloud observability. The stock's 88.7% YTD surge suggests much optimism is priced in, requiring continued execution to justify premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →
